Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
800 participants in 2 patient groups
Loading...
Central trial contact
Clinical Trials Intake
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal